IDEXX Laboratories, Inc. — Q1 2012 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three months ended March 31, 2012, compared with the three months ended March 31, 2011. IDEXX provides veterinary diagnostic and information-management products and services, water-quality products, livestock and poultry diagnostics, dairy testing products, and human point-of-care diagnostics.
The Companion Animal Group represented approximately 83% of consolidated revenue and was the principal growth driver. Approximately 41% of revenue came from customers outside the United States.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Total revenue | $322.7 million | $292.7 million | +10.3% |
| Gross profit | $174.8 million | $154.9 million | +12.8% |
| Gross margin | 54.2% | 52.9% | +130 bps |
| Income from operations | $60.4 million | $53.5 million | +12.8% |
| Operating margin | 18.7% | 18.3% | +40 bps |
| Net income attributable to IDEXX | $40.7 million | $36.6 million | +11.3% |
| Diluted EPS | $0.72 | $0.62 | +16.1% |
| Net cash provided by operating activities | $15.2 million | $25.2 million | -$10.0 million |
| Capital expenditures | $9.4 million | $9.6 million | -$0.1 million |
Revenue growth was led by CAG revenue of $268.1 million, up 11.4%, including organic growth of 10.4%. CAG reference laboratory diagnostic and consulting services increased 14.3%, rapid assay products increased 13.1%, and instruments and consumables increased 8.6%. Water revenue increased 3.3%, while LPD revenue declined 7.3%, primarily because of reduced European Union BSE testing requirements.
Cash and cash equivalents were $185.5 million at March 31, 2012, versus $183.9 million at December 31, 2011. Working capital was $107.6 million, compared with $87.3 million at year-end. The company had $254.0 million outstanding under its $300 million revolving credit facility and $45.0 million of remaining borrowing availability, before the $1.0 million reduction for a letter of credit. Total debt was approximately $257.2 million, including current and long-term debt.
Operating cash flow was reduced by increases in accounts receivable and inventories, a $6.3 million royalty prepayment, and other working-capital uses. Financing uses included $27.6 million of common-stock repurchases. The company remained in compliance with its credit-facility covenants, including the 3-to-1 consolidated leverage-ratio requirement.
Material changes versus the prior comparable period
- Consolidated revenue increased $30.0 million, with CAG contributing $27.5 million of the increase.
- Gross-margin expansion reflected lower manufacturing costs, production-volume efficiencies, and more favorable hedging results.
- Operating expenses increased 12.8%, primarily from higher personnel, information-technology, research and development, and sales and marketing costs.
- Interest expense increased to $1.2 million from $0.7 million because of higher average borrowings.
- The effective tax rate increased to 31.7% from 31.2%, primarily because federal research and development tax incentives were unavailable in 2012.
- Operating cash flow declined despite higher earnings because of working-capital movements and the royalty prepayment.
- Shares repurchased in the open market declined to 333,481 from 538,000, while the average repurchase price increased to $82.85 from $74.21.
- Effective January 1, 2012, revenue from substantially all U.S. distributors was recognized upon delivery rather than shipment; management stated that the change had no material financial impact.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide explicit full-year revenue or earnings guidance. Management described itself as cautiously optimistic that improving U.S. economic conditions and patient-visit trends would gradually reduce pressure on growth, while noting continued economic challenges in parts of Europe.
The 2012 capital-expenditure plan was approximately $60 million, including approximately $13 million for expansion of the Westbrook, Maine headquarters. Management stated that cash on hand, operating cash generation, and available borrowings should fund operations, capital requirements, and strategic growth needs for at least the next twelve months.
The FTC continued investigating IDEXX’s marketing and sales practices, particularly relationships with the three largest U.S. distributors. IDEXX planned to seek modification of one distributor agreement to permit the distributor to carry competing products, with effectiveness expected no later than January 1, 2013, although no outcome was assured. Potential remedies could restrict sales and marketing practices, but the company believed any required changes would not materially adversely affect its financial statements.
- Key operating risks include distributor purchasing volatility, distributor concentration, competition, economic weakness affecting veterinary visits and capital purchases, foreign-currency exposure, regulatory approvals, and reliance on sole- or single-source suppliers.
- Approximately $184 million of cash was held by foreign subsidiaries and was subject to material repatriation tax effects.
- LPD results remained exposed to further changes in European BSE-testing requirements and disease-testing demand.
- Foreign-currency hedges generated a favorable effect relative to the prior year; approximately $1.5 million of net gains in accumulated other comprehensive income were expected to be reclassified into earnings within twelve months, assuming exchange and interest rates remained unchanged.
- There were no material changes in internal control over financial reporting, and management concluded that disclosure controls were effective.
Important facts for investors to verify
- Whether CAG organic growth, particularly reference laboratory and rapid assay growth, was sustained in subsequent quarters.
- The effect of the FTC investigation and any modified national-distributor agreement on pricing, distributor compensation, exclusivity, and sales volumes.
- Whether working-capital usage normalized and operating cash flow converted earnings at the expected rate.
- Progress and funding of the approximately $60 million 2012 capital-expenditure plan.
- Revolving-credit borrowings, remaining availability, interest expense, and continued compliance with leverage covenants.
- Exposure to European economic conditions, foreign-exchange movements, and further reductions in BSE testing.
- Whether gross-margin improvement from manufacturing efficiencies and hedging was recurring or period-specific.